Trazodone

CAT: 0804-HY-B0478A-01Size: 25 mgDry Ice: NoHazardous: No
CAT#:0804-HY-B0478A-01Size:25 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Trazodone (AF-1161 free base) is a triazolopyridine derivative that belongs to the class of serotonin receptor antagonists and reuptake inhibitors (SARIs) . Trazodone has anti-depressant and anti-insomnious activity. Trazodone exerts antagonistic properties against a1- and a2-adrenergic receptors and histamine H1 receptors, with minimal anticholinergic effects[1].
CAS Number
[19794-93-5]
Product Name Alternative
AF-1161 (free base)
UNSPSC
12352005
Hazard Statement
H315-H319-H320
Target
5-HT Receptor; Adrenergic Receptor; Histamine Receptor; Serotonin Transporter
Type
Reference compound
Related Pathways
GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling
Applications
Neuroscience-Neuromodulation
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/trazodone.html
Concentration
10mM
Purity
99.84
Solubility
DMSO : 5 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C1N(CCCN2CCN(C3=CC=CC(Cl)=C3)CC2)N=C4C=CC=CN41
Molecular Formula
C19H22ClN5O
Molecular Weight
371.86
Precautions
P264-P280-P302+P352-P305+P351+P338-P362
References & Citations
[1]Fagiolini A, et, al. Rediscovering trazodone for the treatment of major depressive disorder. CNS Drugs. 2012 Dec;26 (12) :1033-49.|[2]Brogden, R. N., et al., (1981) . Trazodone: a review of its pharmacological properties and therapeutic use in depression and anxiety. Drugs, 21 (6), 401–429.|[3]Raffa, R. B., et al., (1992) . Etoperidone, trazodone and MCPP: in vitro and in vivo identification of serotonin 5-HT1A (antagonistic) activity. Psychopharmacology, 108 (3), 320–326.|[4]Ghanbari, R., et al., (2010) . Sustained administration of trazodone enhances serotonergic neurotransmission: in vivo electrophysiological study in the rat brain. The Journal of pharmacology and experimental therapeutics, 335 (1), 197–206.|[5]Jay AR, Krotscheck U, Parsley E, Benson L, Kravitz A, Mulligan A, Silva J, Mohammed H, Schwark WS. Pharmacokinetics, bioavailability, and hemodynamic effects of trazodone after intravenous and oral administration of a single dose to dogs. Am J Vet Res. 2013 Nov;74 (11) :1450-6.|[6]Daniele S, et al. Trazodone treatment protects neuronal-like cells from inflammatory insult by inhibiting NF-κB, p38 and JNK. Cell Signal. 2015 Aug;27 (8) :1609-29.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
Launched
Citation 01
Anal Bioanal Chem. 2025 Jul;417 (16) :3703-3714.|Int Immunopharmacol. 2025 Jan 6:147:113969.|ACS Omega. 2025 Oct 17;10 (42) :50208-50217.|Clin Chem. 2019 Dec;65 (12) :1522-1531. |University of Cambridge. 2023 Feb.|University of South Carolina. 2025.

Related Products

CatalogName

Popular Products